Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$959.8MCash on Hand
21.9mo Cash Runway
25.1%Short Interest
$92.72Analyst Target (18)
Follow VKTX by emailGet an email when VKTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VKTX, unsubscribe in one click. Privacy
📣 What VKTX Says Is Next
this quarter · “The company expects to complete the SAD study later this quarter and initiate a 4 week multiple ascending dose (MAD) study of VK3019 in 1Q27.”
Company press release, Oct 28, 2026 · SEC filing
in 2027 · “The company expects the results from Part 2 of this study to be available in 2027.”
Company press release, Oct 28, 2026 · SEC filing
early 2027 · “Importantly, results from this study will help inform the selection of doses in the upcoming VANQUISH extension studies, expected to begin in early 2027.”
Company press release, Oct 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 29, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 28, 2026 ·
Earnings Reported Q3 2026 results with $960 million cash at quarter-end after upsized public offerings of common stock and convertible senior notes. Announced initiation of SUNRISE oral Phase 3 trials for VK2735, positive VK2735 maintenance study results, and Part 2 initiation. Form 8-K · SEC filing · Press release
Sep 28, 2026 ·
Financing Viking priced a 7,857,143-share common stock offering at $35.00 per share, with underwriters exercising a 1,178,571-share option in full, for net proceeds of about $297.0 million. It also sold $225,000,000 of 2.00% convertible senior notes due 2032, with a $33,750,000 option exercised in full. Form 8-K · SEC filing
Sep 25, 2026 ·
Financing Viking Therapeutics is offering 7,857,143 shares of common stock at $35.00 per share, for gross proceeds of $275,000,005. Underwriters have a 30-day option to buy up to 1,178,571 more shares. A concurrent $225,000,000 convertible note offering is also underway. Form 424B5 · SEC filing
Sep 25, 2026 ·
Financing Viking Therapeutics is offering $225,000,000 of 2.00% convertible senior notes due 2032, with an option for an additional $33,750,000 to cover over-allotments. The initial conversion price is approximately $50.75 per share, and the notes are priced at 100.000% of principal, with underwriting discounts of 3.000%. Form 424B5 · SEC filing
Sep 23, 2026 ·
Financing Viking Therapeutics filed a preliminary prospectus for a proposed offering of common stock, with the number of shares and price still blank. It is concurrent with a separate convertible senior notes offering due 2032. The last reported sale price was $40.85 per share on September 22, 2026. Form 424B5 · SEC filing
Sep 23, 2026 ·
Financing Viking Therapeutics proposed a public offering of convertible senior notes due 2032, with the principal amount, interest rate and conversion price left blank. A concurrent common stock offering is planned, and the stock closed at $40.85 on September 22, 2026. Form 424B5 · SEC filing
Sep 22, 2026 ·
Clinical trial Viking reported top-line maintenance study results for VK2735. Weekly 17.5 mg dosing gave 22% placebo-adjusted weight loss at Week 33 (weekly dosing, no plateau observed). Every-other-week dosing maintained up to 97% of weight loss, versus 61% for placebo. GI adverse event rates were similar to placebo. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 1 · Recruiting · A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities Registry primary completion date, not a results date
Jul 2027 · Phase 3 · Active Trial · VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Registry primary completion date, not a results date
Jul 2027 · Phase 3 · Active Trial · VK2735 for Weight Management Phase 3 Registry primary completion date, not a results date
Jul 2028 · Phase 3 · Upcoming Trial · Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) Registry primary completion date, not a results date
Oct 2028 · Phase 3 · Upcoming Trial · Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
VKTX holds $959.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $131.7M/quarter from operations,
an estimated runway of 21.9 months at that rate (BioRadar estimate, not company guidance).
Share count 127,522,189 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
📈 Recent Insider Activity (Form 4)
Trade date
Insider
Transaction
Shares
Price
Owned after
2026-08-01 filed 2026-08-07
Kelly-Gemmell Dorothy Elizabeth
Award (A)
6,333
–
6,333
2026-08-01 filed 2026-08-07
Kelly-Gemmell Dorothy Elizabeth
Option award (A)
40,800
–
–
2026-07-29 filed 2026-07-29
Lian Brian
Sale (S)
148,517
$33.32
2,572,441
2026-07-29 filed 2026-07-29
Mancini Marianna
Sale (S)
18,217
$33.47
422,760
2026-07-29 filed 2026-07-29
ZANTE GREG
Sale (S)
21,217
$33.47
212,204
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
Get the full VKTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VKTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.